Genetics and biology of pancreatic ductal adenocarcinoma
- PMID: 16702400
- DOI: 10.1101/gad.1415606
Genetics and biology of pancreatic ductal adenocarcinoma
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the United States with a median survival of <6 mo and a dismal 5-yr survival rate of 3%-5%. The cancer's lethal nature stems from its propensity to rapidly disseminate to the lymphatic system and distant organs. This aggressive biology and resistance to conventional and targeted therapeutic agents leads to a typical clinical presentation of incurable disease at the time of diagnosis. The well-defined serial histopathologic picture and accompanying molecular profiles of PDAC and its precursor lesions have provided the framework for emerging basic and translational research. Recent advances include insights into the cancer's cellular origins, high-resolution genomic profiles pointing to potential new therapeutic targets, and refined mouse models reflecting both the genetics and histopathologic evolution of human PDAC. This confluence of developments offers the opportunity for accelerated discovery and the future promise of improved treatment.
Similar articles
-
[Pancreatic ductal adenocarcinoma].Internist (Berl). 2018 Aug;59(8):805-822. doi: 10.1007/s00108-018-0460-z. Internist (Berl). 2018. PMID: 29980819 Review. German.
-
Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse Model.Am J Pathol. 2016 Nov;186(11):2934-2944. doi: 10.1016/j.ajpath.2016.07.025. Epub 2016 Sep 14. Am J Pathol. 2016. PMID: 27639167
-
GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice.Proc Natl Acad Sci U S A. 2017 May 16;114(20):E4020-E4029. doi: 10.1073/pnas.1616060114. Epub 2017 May 1. Proc Natl Acad Sci U S A. 2017. PMID: 28461470 Free PMC article.
-
Organoid models for translational pancreatic cancer research.Curr Opin Genet Dev. 2019 Feb;54:7-11. doi: 10.1016/j.gde.2019.02.003. Epub 2019 Mar 4. Curr Opin Genet Dev. 2019. PMID: 30844513 Free PMC article. Review.
-
The biological underpinnings of therapeutic resistance in pancreatic cancer.Genes Dev. 2021 Jul 1;35(13-14):940-962. doi: 10.1101/gad.348523.121. Epub 2021 Jun 11. Genes Dev. 2021. PMID: 34117095 Free PMC article. Review.
Cited by
-
TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors.Nat Cell Biol. 2015 May;17(5):615-626. doi: 10.1038/ncb3160. Epub 2015 Apr 27. Nat Cell Biol. 2015. PMID: 25915126 Free PMC article.
-
Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41.J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S80-S90. doi: 10.21037/jgo-20-238. J Gastrointest Oncol. 2021. PMID: 33968428 Free PMC article.
-
Cholesterol Activates Cyclic AMP Signaling in Metaplastic Acinar Cells.Metabolites. 2021 Feb 26;11(3):141. doi: 10.3390/metabo11030141. Metabolites. 2021. PMID: 33652890 Free PMC article.
-
Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation.Cell Rep Med. 2024 Sep 17;5(9):101711. doi: 10.1016/j.xcrm.2024.101711. Epub 2024 Sep 3. Cell Rep Med. 2024. PMID: 39232498 Free PMC article.
-
A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.Mol Med. 2020 Jun 17;26(1):59. doi: 10.1186/s10020-020-00183-1. Mol Med. 2020. PMID: 32552660 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
